Gout as a cardiovascular risk factor

被引:0
|
作者
Hernandez Batista, Sulema de la Caridad [1 ]
Villafuerte Morales, Johanna Elizabeth [1 ]
Chimbolema Mullo, Sergio Orlando [2 ]
Pilamunga Lema, Cesar Lenin [1 ]
机构
[1] Escuela Super Politecn Chimborazo, Riobamba, Chimborazo, Ecuador
[2] Univ Nacl Chimborazo, Riobamba, Chimborazo, Ecuador
来源
REVISTA CUBANA DE REUMATOLOGIA | 2021年 / 23卷 / 03期
关键词
cardiovascular disease; rheumatic disease; gout; arterial hypertension;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Gout is a chronic inflammatory disease that generally progresses with added hyperuricemia. Objective: To identify the presence of cardiovascular involvement in patients with a confirmed diagnosis of gouty arthropathy. Methodology: A basic, non-experimental, descriptive, retrospective and mixed-focus research was developed. The universe consisted of 69 patients treated in first-level health care units in the city of Riobamba during the period between January 2019 and January 2021. The sample was made up of a total of 60 patients. A review of the clinical history of the patients was carried out to obtain the necessary information. Result: Average age of 53.02 years. 35.00% of them presented at least one associated comorbidity, where diabetes mellitus was the most represented (57.14%). with presence of comorbidities. 71.67% of the patients had normal blood uric acid values at the time of diagnosis and 18.33% had some type of kidney damage. 36.67% of the patients with gout also presented cardiovascular disease, where arterial hypertension (59.09% was the most frequently reported. Conclusions: Gouty arthropathy is a disease that theoretically generates a high percentage of cardiovascular diseases within of which arterial hypertension and heart failure stand out.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Hyperuricaemia, gout and cardiovascular risk after liver transplantation
    Neal, D
    Tom, B
    Gimson, A
    Gibbs, P
    Alexander, G
    JOURNAL OF HEPATOLOGY, 2002, 36 : 41 - 41
  • [22] Cardiovascular risk for nearest 10 years in patients with gout
    Barskova, V. G.
    Ilinykh, E. V.
    Nassonov, E. L.
    Nassonova, V. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 431 - 431
  • [23] Gout, hyperuricemia, and the risk of cardiovascular disease: Cause and effect?
    Shah A.
    Keenan R.T.
    Current Rheumatology Reports, 2010, 12 (2) : 118 - 124
  • [24] Febuxostat a new drug for treatment of gout. Increased cardiovascular risk in gout patients?
    Christalla, P.
    Wittkoepper, K.
    El-Armouche, A.
    KARDIOLOGE, 2011, 5 (01): : 45 - 49
  • [25] Is metabolic syndrome a modifiable risk factor for gout?
    不详
    SAUDI MEDICAL JOURNAL, 2023, 44 (05) : 522 - 522
  • [26] Gout: An Independent Risk Factor for Heart Failure
    Kim, Chang H.
    Chami, Ahmad T.
    Nadeem, Fahd
    Al-Kindi, Sadeer G.
    Oliveira, Guilherme H.
    JOURNAL OF CARDIAC FAILURE, 2016, 22 (08) : S75 - S75
  • [27] Cardiovascular risk in patients with new gout: should we reclassify the risk?
    Gamala, M.
    Jacobs, J. W. G.
    Linn-Rasker, S. P.
    Nix, M.
    Heggelman, B. G. F.
    Pasker-de Jong, P. C. M.
    van Laar, J. M.
    Klaasen, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (03) : 533 - 535
  • [28] CARDIOVASCULAR GOUT
    Mikhnevich, Eleanora
    Pavlovich, Tatiana
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1907 - 1907
  • [29] Cardiovascular risk associated with allopurinol or benzbromarone treatment in patients with gout
    Eun, Yeonghee
    Han, Heewon
    Kim, Kyunga
    Kang, Seonyoung
    Lee, Seulkee
    Kim, Hyungjin
    Lee, Jaejoon
    Koh, Eun-Mi
    Cha, Hoon-Suk
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2022, 14
  • [30] Modifiable risk factors and incident cardiovascular events in gout patients
    Ning, Y.
    Tang, M.
    An, J.
    Zhao, C.
    Zhang, J.
    Gao, W.
    Wei, M.
    Tse, G.
    Chan, J.
    Waintraub, X.
    Lei, X.
    Saguner, A.
    Yan, Y.
    Wang, D.
    Li, G.
    EUROPEAN HEART JOURNAL, 2024, 45